This study investigated the effects of low-dose 1cp-LSD, a prodrug of LSD, on canine anxiety, while exploring the influence of owner psychopathology on treatment outcomes. Seven dogs exhibiting anxiety-related behaviors were recruited and received 2.5, 5, or 10 µg of 1cp-LSD orally every three days for 30 days. One additional dog, which did not meet clinical criteria for anxiety but whose owner perceived it as anxious, received a placebo (saccharin) as an observational case. Anxiety levels were assessed using validated scales at baseline, post-treatment, and one month after treatment cessation. Owners’ neuroticism and psychopathological dimensions were evaluated using the IPIP and SA-45 scales. Linear regression analyses examined associations between anxiety reduction, administered dose, and owner psychological traits. A significant reduction in separation anxiety scores was observed post-treatment (mean: 11.3 ± 3.0, p = 0.023). Higher 1cp-LSD doses correlated with greater anxiety reduction (B = −1.15, 95% CI = [−2.29, −0.003], p = 0.050). Additionally, higher owner psychoticism scores were associated with smaller improvements in canine anxiety (p = 0.035). Anxiety levels remained low one month after treatment, with significant associations between canine anxiety and the owners’ hostility, interpersonal sensitivity, and paranoid ideation. These findings support the potential role of low-dose serotonergic psychedelics in managing canine anxiety and suggest an association between caregiver psychological traits and treatment outcomes. The sustained reduction in anxiety behaviors also suggests a meaningful and lasting improvement in animal welfare. However, significant results should be interpreted cautiously due to the small sample size. Further blinded, controlled studies are needed to validate these preliminary observations and assess broader applications in veterinary behavioral medicine.

Anxiety affects 14–20% of dogs. Pharmacological treatments often fail. Psychedelics have shown to be useful for anxiety and depression in humans, but their veterinary use remains unexplored. We aimed to determine the effects of low-dose 1-cyclopropionyl-d-lysergic acid diethylamide (1cp-LSD) administered in a single dose to a dog, to observe the effect and establish the safety of the substance. The patient was a 13-year-old female dog, weighing 13 kg, mixed breed, and spayed. A total of 5 µg was administered orally, equivalent to 0.38 µg/kg. The animal has had a history of separation related behavioral problems throughout her life. To objectively assess the degree of anxiety in the dog, a validated scale was utilized. The trial was scheduled at the house where the animal lives. The owner was present throughout the experience. Informed consent was obtained prior to the assay. The trial began at 12:15 p.m. on January 10, 2024, lasting for 5 and a half hours. The response to anxiety-inducing stimuli was equally anxious during the first two hours. From that point onwards, a significant change in the animal’s behavior was observed, with no signs/mild signs of anxiety. The trial concluded without any adverse effects on the animal. The patient did not show signs of having a psychedelic experience. This is the first time that a study of this nature has been conducted and reported in the canine species. 1cp-LSD proved to be safe and exerted the desired effect on the animal’s behavior, significantly reducing the patient’s anxiety.

Background: Veterinary students experience high levels of mental health issues. Objectives: To analyze substance use, internet consumption, and mental health factors among students and academic staff of the Faculty of Veterinary Medicine of the University of Las Palmas de Gran Canaria, identifying factors associated with well-being and dissatisfaction. Methods: A total of 226 respondents participated, including 177 students (78.3%) and 49 staff members (21.7%). Data were collected between 30 October 2024 and 14 January 2025 using an adapted EDADES-based survey assessing substance use (alcohol, tobacco, electronic nicotine delivery systems (ENDSs), anxiolytics, and illicit drugs), internet habits, and psychological well-being among participants. Binary logistic regression was applied to identify factors associated with dissatisfaction. Results: Students exhibited higher binge drinking rates, greater ENDS consumption, and more problematic internet use than staff. Significant gender differences were observed, with females reporting greater emotional distress and a higher need for psychological support. Water pipe use (OR = 2.79, 95% CI = 1.45–5.38), anxiolytic consumption (OR = 2.31, 95% CI = 1.08–4.92), and excessive internet use (OR = 4.83, 95% CI = 1.66–14.1) were associated with lower overall satisfaction. Age was inversely associated with dissatisfaction (OR = 0.96, 95% CI = 0.94–0.98), and females were significantly more likely to report dissatisfaction (OR = 2.79, 95% CI = 1.45–5.38). Conclusions: Veterinary students exhibited higher psychological distress than teaching staff. Implementing targeted interventions to address substance use and internet habits is needed in order to enhance psychological well-being.

Low-dose psychedelics have shown potential in modulating chronic pain in humans, yet their application in veterinary medicine remains unexplored. This study protocol proposes to investigate the therapeutic potential of low-dose oral administration of 1-cyclopropionyl-D-lysergic acid diethylamide (1cp-LSD), a legal LSD analogue in certain countries, for the management of chronic pain in privately owned dogs with osteoarthritis. The study will employ a randomized, placebo-controlled design with caregivers blinded to treatment allocation. A cohort of about 24 dogs previously diagnosed with osteoarthritis, will orally receive sub-perceptual, intermittent doses of 1cp-LSD over a 30-day period, while maintaining their standard analgesic regimens to safeguard animal welfare. Outcome measures will include the Canine Brief Pain Inventory and caregiver-reported assessments, including the Treatment Expectation Questionnaire (TEX-Q), to evaluate both pharmacological efficacy and the influence of caregiver expectations as an indirect indicator of placebo effects as a secondary aim. The study anticipates a reduction in pain scores among treated dogs, potentially modulated by caregiver expectations. However, the sustained effect of 1cp-LSD in osteoarthritis remains uncertain due to interactions with inflammatory mediators. Limitations include the lack of established dose–response relationships, small cohort size, and variability in caregiver perceptions, which will be analyzed descriptively. The protocol establishes a comprehensive and methodologically framework to evaluate both the pharmacological therapeutic effects of low-dose psychedelics in managing chronic osteoarthritic pain and the psychological factors that may influence perceived outcomes.

Shelter environments frequently expose dogs to chronic stress and anxiety, which can compromise their welfare and reduce their chances of adoption. Recent interest in psychedelic-assisted approaches has suggested potential therapeutic applications in veterinary behavioral medicine, although empirical evidence remains scarce. This study aimed to evaluate the combined effects of low-dose 1-cyclopropionyl lysergic acid diethylamide (1cp-LSD), a legal lysergamide prodrug of LSD in several countries, and ethological intervention (EI) on the behavior and welfare of shelter dogs. Twenty dogs were randomly assigned to four groups: pharmacological intervention, ethological intervention, combined treatment, or control. The ethological sessions were conducted by veterinary behaviorists, and pharmacological treatment consisted of 10 µg of 1cp-LSD administered orally for three weeks. Blinded evaluators assessed animals using validated anxiety and welfare scales, including a treatment expectation scale, before, during and after the intervention. Results showed that the combined condition consistently outperformed single interventions, significantly enhancing sociability, calmness, and positive emotional reactivity. Importantly, these improvements persisted for three weeks following treatment cessation, indicating sustained benefits beyond the active intervention phase. These findings provide preliminary evidence for the potential of integrating low doses of psychedelics with behavioral therapy in shelter settings. Future studies with larger cohorts and refined pharmacokinetic data are required to confirm safety, elucidate mechanisms, and optimize protocols for clinical application in veterinary practice.

Free-roaming cats may contribute to zoonotic risk via parasites and other eukaryotic taxa, yet surveillance in protected island settings is limited and conventional coprology can miss low-intensity or degraded signals. We conducted a cross-sectional 18S rRNA metabarcoding survey to establish a baseline profile of potentially pathogenic eukaryotes in community cats from La Graciosa (Natura 2000, Canary Islands, Spain) prior to large-scale antiparasitic interventions. We analysed 152 faecal samples, including fresh samples collected during a high-throughput TNR campaign (n = 37) and dry environmental deposits (n = 115). Host amplification was reduced using a feline 18S blocking primer; libraries were sequenced with Oxford Nanopore technology; and taxonomy was assigned using SILVA-based classifiers with downstream filtering for veterinary/zoonotic relevance. After quality control, 72 eukaryotic taxa were retained and DNA from at least 24 potentially pathogenic taxa was detected. Dipylidium caninum was most frequent (74.3%; 113/152), and opportunistic fungi/yeasts were common (e.g., Pichia kudriavzevii 42.4%, Diutina catenulata 31.5%). Zoonotic protozoa showed low-to-moderate detection frequency (Acanthamoeba castellanii 13.3%, Toxoplasma gondii 7.9%, Balamuthia mandrillaris 4.6%). Overall richness did not differ between fresh and dry samples (p > 0.05), but fresh samples contained higher richness of potentially pathogenic taxa (p < 0.01).